WATCHMAN FLX device on white background with FDA approved orange badge.


Left Atrial Appendage Closure Device

featuring HEMOCOAT™ Technology

The WATCHMAN FLX Pro LAAC Device – Patient Success

Hear Miguel’s story on how the advancements of the WATCHMAN FLX Pro Device made it the clear choice to reduce the risk of stroke and help him to live a better life.

WATCHMAN FLX Pro pre-clinical data

The fluoropolymer-coated WATCHMAN FLX Pro device showed significantly less thrombus and reduced inflammation in a challenging canine model. Mechanistic studies demonstrated that the WATCHMAN FLX Pro device binds more albumin, leading to reduced platelet activation, less inflammation, and greater endothelial coverage (EC).1

WATCHMAN TruSteer™ Access System

Designed to improve implant success, the WATCHMAN TruSteer™ Access System optimizes coaxial device positioning in the widest range of LAA anatomies.

Learn more about WATCHMAN Integrated LAAC Solutions

Access resources

Access WATCHMAN resources by visiting our WATCHMAN Download Center.

Stay connected

Stay informed with the latest information about WATCHMAN integrated LAAC solutions

Rep visit

Connect with a local representative to learn more about WATCHMAN Integrated LAAC Solutions.


  1. Saliba et al. JACC: Clinical Electrophysiology, May 2023. Bench testing or pre-clinical study results may not necessarily be indicative of clinical performance. N=12 in a pre-clinical canine study.